NPPA raps Cipla, Ranbaxy for overcharging

Leading pharmaceutical firms such as Cipla and Ranbaxy are among those pulled up by the drug price regulator, National Pharmaceuticals Pricing Authority (NPPA), for overcharging.

According to NPPA website, as on October 31, the total estimated overcharged amount, including interest, by various pharmaceutical firms since the inception of NPPA in 1997 was Rs 2,208.35 crore. But so far, the authority could recover a paltry Rs 202.20 crore from this and is fighting litigation in various courts with the companies to recover the rest of the sum.